Global

Drug Development Platforms (iPS Technology, RNA CDMO, Bioprinter)

CONTACT US

News

News topics

October 10,2023:

Exhibited at BioJapan 2023 [Japanese only]
October 5,2022:

Exhibited at BioJapan [Japanese only]
April 12,2022:

Exhibited at the International Pharmaceutical Development Expo 2022 [Japanese only]
March 2,2022:

Exhibited at Pharma Lab Expo Osaka [Japanese only]
December 2,2021:

Exhibited at Pharma Lab Expo Tokyo [Japanese only]
May 10,2021:

Elixirgen Scientific released the "Quick-Neuron^™ Plate - MEA 48" human neuronal pharmacological/toxicity evaluation plate, co-developed with Ricoh. [Japanese only]

Press release

July 24,2024:

Elixirgen Scientific and Mitsubishi Tanabe Pharma America Announce a Cell Supply Agreement for the Manufacturing of Human iPSC-Derived CNS Cell Types
July 12,2024:

Elixirgen Scientific Launches Advanced hiPSC-Derived Disease Panel for Alzheimer’s Disease
March 13,2024:

Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement
March 27,2023:

Ricoh made its first investment since the establishment of the "Ricoh Biomedical Startup Fund". [Japanese only]
March 23,2023:

Successfully produced human neuronal cells useful for research on memory mechanisms and the development of therapeutic drugs for central nervous system disorders.
October 7,2022:

The proposal by Ricoh and Elixirgen Scientific Japan was adopted for the Ministry of Economy, Trade and Industry's "Project for the Development of Biopharmaceutical Manufacturing Bases to Strengthen Vaccine Production Systems. [Japanese only]
August 30,2022:

Established a fund to revitalize the mRNA drug discovery market in Japan.
May 17,2022:

Strengthened drug discovery support business using mRNA.

Publication

PAGE TOP